Síndrome coronariana aguda com elevação do segmento St: tratamento medicamentoso (2017)
- Authors:
- Autor USP: NICOLAU, JOSÉ CARLOS - FM
- Unidade: FM
- Subjects: SÍNDROME CORONARIANA AGUDA; FATORES DE RISCO; INFARTO DO MIOCÁRDIO; FÁRMACOS (SISTEMA CARDIOVASCULAR)
- Language: Português
- Imprenta:
- Publisher: Atheneu
- Publisher place: Rio de Janeiro
- Date published: 2017
- ISBN: 9788538808107
- Source:
-
ABNT
NICOLAU, José Carlos e FURTADO, Remo Holanda de Mendonça. Síndrome coronariana aguda com elevação do segmento St: tratamento medicamentoso. SOCESP Cardiologia: Atualizacao e Reciclagem. Tradução . Rio de Janeiro: Atheneu, 2017. . . Acesso em: 12 out. 2024. -
APA
Nicolau, J. C., & Furtado, R. H. de M. (2017). Síndrome coronariana aguda com elevação do segmento St: tratamento medicamentoso. In SOCESP Cardiologia: Atualizacao e Reciclagem. Rio de Janeiro: Atheneu. -
NLM
Nicolau JC, Furtado RH de M. Síndrome coronariana aguda com elevação do segmento St: tratamento medicamentoso. In: SOCESP Cardiologia: Atualizacao e Reciclagem. Rio de Janeiro: Atheneu; 2017. [citado 2024 out. 12 ] -
Vancouver
Nicolau JC, Furtado RH de M. Síndrome coronariana aguda com elevação do segmento St: tratamento medicamentoso. In: SOCESP Cardiologia: Atualizacao e Reciclagem. Rio de Janeiro: Atheneu; 2017. [citado 2024 out. 12 ] - Ticagrelor versus clopidogrel in patients with STEMI treated with fibrinolysis TREAT trial
- Ticagrelor vs Clopidogrel After Fibrinolytic Therapy in Patients With ST-Elevation Myocardial Infarction: A Randomized Clinical Trial (vol 3, pg 391, 2018)
- Effects of Dapagliflozin on Symptoms, Function, and Quality of Life in Patients With Heart Failure and Reduced Ejection Fraction Results From the DAPA-HF Trial
- Efficacy and Safety of Dapagliflozin in Heart Failure With Reduced Ejection Fraction According to Age Insights From DAPA-HF
- Effect of alirocumab on mortality after acute coronary syndromes an analysis of the ODYSSEY OUTCOMES randomized clinical trial
- Predicting risk of cardiovascular events 1 to 3 years post-myocardial infarction using a global registry
- Long-term ticagrelor for secondary prevention in patients with prior myocardial infarction and no history of coronary stenting: insights from PEGASUS-TIMI 54
- Two-year outcomes among stable high-risk patients following acute MI. Insights from a global registry in 25 countries
- Anti-Thrombotic Therapy to Ameliorate Complications of COVID-19 (ATTACC): Study design and methodology for an international, adaptive Bayesian randomized controlled trial
- Rationale and design of the long-Term rIsk, clinical manaGement, and healthcare Resource utilization of stable coronary artery dISease in post-myocardial infarction patients (TIGRIS) study
How to cite
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas